期刊
ANTIOXIDANTS
卷 9, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/antiox9070600
关键词
N-acetylcysteine; oxidative stress; Parkinson's disease; neurodegeneration; antioxidant capacity; deferoxamine; iron
资金
- University ofWestminster, Faculty of Science and Technology
Oxidative stress is a key mediator in the development and progression of Parkinson's disease (PD). The antioxidantN-acetylcysteine (NAC) has generated interest as a disease-modifying therapy for PD but is limited due to poor bioavailability, a short half-life, and limited access to the brain. The aim of this study was to formulate and utilise mitochondria-targeted nanocarriers for delivery of NAC alone and in combination with the iron chelator deferoxamine (DFO), and assess their ability to protect against oxidative stress in a cellular rotenone PD model. Pluronic F68 (P68) and dequalinium (DQA) nanocarriers were prepared by a modified thin-film hydration method. An MTT assay assessed cell viability and iron status was measured using a ferrozine assay and ferritin immunoassay. For oxidative stress, a modified cellular antioxidant activity assay and the thiobarbituric acid-reactive substances assay and mitochondrial hydroxyl assay were utilised. Overall, this study demonstrates, for the first time, successful formulation of NAC and NAC + DFO into P68 + DQA nanocarriers for neuronal delivery. The results indicate that NAC and NAC + DFO nanocarriers have the potential characteristics to access the brain and that 1000 mu M P68 + DQA NAC exhibited the strongest ability to protect against reduced cell viability (p= 0.0001), increased iron (p= 0.0033) and oxidative stress (p <= 0.0003). These NAC nanocarriers therefore demonstrate significant potential to be transitioned for further preclinical testing for PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据